Specialty practices document a level of product and treatment detail that a standard diagnosis code does not begin to carry. A dermatologist recommends an active ingredient at a particular concentration alongside a prescription. A gynecologist orders a compounded preparation with a specific strength and duration. An administrator needs to know which vendor supplied which lot.

The usual explanation for why this detail gets lost is that templates are inflexible. That is part of it. The larger reason is more specific, and once you see it the whole problem makes sense.

The Real Gap: Products With No Code

An electronic record handles prescription medication well because prescription medication has an identity the software understands. Approved drugs carry a National Drug Code, and a normalized name in RxNorm. That identity is what lets a medication be selected from a list, electronically prescribed, checked for interactions, reconciled at the next visit, and counted in a report.

Now consider what a specialty practice actually recommends in a given week:

• Compounded preparations made for one patient by a compounding pharmacy, which generally carry no NDC at all.
• Cosmeceuticals and cosmetic ingredients, regulated as cosmetics rather than drugs, and therefore not approved or coded as medication.
• Over the counter products the patient bought themselves, often online, which never passed through a prescription workflow.
• Supplements, which sit outside the drug framework entirely.

None of these can be selected from the drug database, e-prescribed, interaction checked or reconciled. So they land in free text, and free text cannot be searched, trended, reported on, or reliably handed to a covering provider. That is the mechanism behind “the detail got lost.” It is not carelessness. It is a data model that only recognizes one class of product.

Which means the question to ask a vendor is not whether templates are configurable. It is what the system does with a therapy that has no code: whether there is a structured place for it, whether it appears on the medication list, and whether it can be found again in a query.

Dermatology: Ingredient Level Recommendations

A dermatology visit routinely produces two kinds of recommendation at once. A prescription, which the record handles. And a regimen built from products that are not prescriptions, which it usually does not.

A patient treated for texture or pigmentation may be advised to add an ingredient such as an alpha hydroxy acid at a stated concentration, alongside a prescribed topical. The FDA’s guidance on alpha hydroxy acids in cosmetics is itself a good illustration of why this matters clinically rather than commercially, since it addresses sun sensitivity, which is exactly the kind of counseling point that needs to be in the record and repeated consistently rather than delivered once and forgotten.

Capturing that as structured data, rather than on a printed handout the patient loses, does four things a note cannot. The recommendation is present at the next visit. The response can be recorded against it. It stays consistent when the patient sees a different provider in the same practice. And it becomes queryable, so when a formulation changes or a product is recalled, the practice can produce a list of affected patients in a minute rather than a chart review.

A dermatology EHR that ties regimen fields to serial photography earns its keep here, because in dermatology the response to a recommendation is visual and belongs next to the recommendation that produced it.

Gynecology: Compounded and Patient Purchased Products

Gynecology hits the same wall from a different direction, and often with higher stakes, because a meaningful share of what patients are using was never prescribed at all.

Two distinct cases have to be captured. The first is a compounded preparation ordered from a compounding pharmacy for one patient, where exact strength, base, quantity and duration all matter and none of it arrives with a standard code. The second is the product the patient bought online before the appointment and is already using.

Intravaginal boric acid suppositories are a clear example of the category. Boric acid for intravaginal use is not an FDA approved drug product, it is compounded when used under clinical direction, and the FDA has issued warning letters to marketers of over the counter boric acid vaginal suppositories on the basis that therapeutic claims make them unapproved and misbranded drugs. Patients nonetheless buy them from retail marketplaces in volume.

For the practice, that produces a specific documentation obligation. What the patient is actually using has to appear on the medication list even though it was never prescribed, with enough detail that a covering provider or a refill request can be handled accurately, and with the chronology intact so nobody repeats an approach that already failed. An OBGYN EHR that treats non prescription and compounded items as first class entries rather than free text is doing the thing the specialty actually requires.

It is also worth recording where a patient obtained something, because a product bought from a marketplace has no dispensing record anywhere else, and your chart is the only place that information will ever exist.

Supply and Vendor Tracking, Realistically

Documentation is not the only place specialty practices carry detail that generic systems drop. Inventory and vendor management matter in any practice holding consumables, and in dermatology and gynecology the consumables are a real cost line.

Practice management systems track products, lots, expiry dates and suppliers as standard. Some practices extend that with attributes of their own, including sustainability criteria, since medical supply and regulated waste are a genuine cost and increasingly a procurement consideration. Packaging is one of the attributes that comes up, and the term covers more ground than most buyers expect. The industry’s own explanation of biodegradable plastics is a useful starting point precisely because it shows how much the definitions vary, which is why a purchasing policy built on the word alone tends not to survive contact with a supplier catalog.

Being straightforward about what this is: supplier attribute tagging of that kind is usually custom field work inside practice management software rather than a shipped feature. That is achievable and worth doing if the practice has a policy to enforce. It is not something to expect out of the box.

What Structured Capture Actually Buys

When specialty detail sits in fields rather than paragraphs, four things become possible that were not before:

1. Continuity. A covering provider sees what was recommended, at what strength, and how the patient responded, without reading three notes.
2. Reporting without chart review. Staff can answer “which patients are on this” as a query.
3. Recall and safety. When a formulation changes or a product is withdrawn, the affected list is generated rather than reconstructed.
4. Consistency across turnover. The practice’s approach survives a provider leaving, because it was recorded rather than remembered.

Choosing a Specialty EHR: What to Test

Configurability is the claim every vendor makes. Test the specific thing instead:

1. Add a compounded preparation with strength, base, quantity and duration, and confirm it appears on the medication list rather than in a note.
2. Record a non prescription product the patient is already using, and check whether it reconciles at the next visit.
3. Query your patient base for everyone on a given ingredient or product, and time how long it takes.
4. Record a response against a prior recommendation, then display the two together chronologically.
5. Produce the audit trail showing who changed a regimen and when.

A record that passes those five is a genuine specialty EHR. One that passes two has configurable templates, which is not the same thing and will not feel like it in eighteen months.

Conclusion

Specialty practices lose detail for a reason that is structural rather than behavioral. The record was built around products that carry a code, and a large share of what these specialties recommend does not carry one. Everything else follows from that: the free text, the lost handout, the covering provider starting over, the question nobody can answer with a query.

The fix is not a better template. It is a system that gives coded and uncoded therapies the same standing, so that what a patient is actually using is in the chart as data regardless of whether it came from a pharmacy, a compounder, or a box they bought themselves.